Vargatef ® (nintedanib*) approved in the EU for lung cancer patients with advanced adenocarcinoma after first-line chemotherapy

Vargatef ® (nintedanib*) approved in the EU for lung cancer patients with advanced adenocarcinoma after first-line chemotherapy
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news